CDK4/6 Inhibitors as Upfront Treatment in a Patient with Breast Cancer Presenting with a Clinical Critic Situation: A Case Report and Review of the Literature

CDK4/6 inhibitors have revolutionized the treatment algorithm of luminal metastatic breast cancer, becoming the recommended first-line therapy in association with endocrine therapy. However, due to its theoretically greater and more rapid tumor shrinkage, the upfront use of chemotherapy is considere...

Descripción completa

Detalles Bibliográficos
Autores principales: Targato, Giada, Bortot, Lucia, Dri, Arianna, Bonotto, Marta, Minisini, Alessandro Marco, Fasola, Gianpiero, Mansutti, Mauro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777243/
https://www.ncbi.nlm.nih.gov/pubmed/36547170
http://dx.doi.org/10.3390/curroncol29120756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777243/
https://www.ncbi.nlm.nih.gov/pubmed/36547170
http://dx.doi.org/10.3390/curroncol29120756

Ejemplares similares